PHARMIGENE INCPHARMIGENE INCPHARMIGENE INC

PHARMIGENE INC

No trades
See on Supercharts
Market capitalization
‪681.28 M‬TWD
−1.90TWD
‪−72.65 M‬TWD
‪132.71 M‬TWD
Beta (1Y)
0.20

About PHARMIGENE INC


CEO
Fu Hui Chan
Headquarters
Taipei
Founded
2005
ISIN
TW0007595B13
FIGI
BBG00WK94VY7
Pharmigene, Inc. engages in the manufacturing and sales of pharmaceutical genetic diagnostic products. Its businesses include the provision of functional medical testing services, production and distribution of testing products and diagnostic tools, agency sales of laboratory equipment and consumables and authorization of Carbamazepine, Allopurinol, and Warfarin drugs related patents for genetic testing. The company was founded by Yuan Tsong Chen on September 28, 2005 and is headquartered in Taipei, Taiwan.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 7595 is 13.55 TWD — it has increased by 4.23% in the past 24 hours. Watch PHARMIGENE INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange PHARMIGENE INC stocks are traded under the ticker 7595.
7595 stock has fallen by −1.81% compared to the previous week, the month change is a −6.55% fall, over the last year PHARMIGENE INC has showed a −37.99% decrease.
7595 reached its all-time high on Dec 22, 2020 with the price of 36.00 TWD, and its all-time low was 13.40 TWD and was reached on Nov 30, 2022. View more price dynamics on 7595 chart.
See other stocks reaching their highest and lowest prices.
7595 stock is 16.80% volatile and has beta coefficient of 0.20. Track PHARMIGENE INC stock price on the chart and check out the list of the most volatile stocks — is PHARMIGENE INC there?
Yes, you can track PHARMIGENE INC financials in yearly and quarterly reports right on TradingView.
7595 net income for the last half-year is ‪−48.69 M‬ TWD, while the previous report showed ‪−43.98 M‬ TWD of net income which accounts for −10.71% change. Track more PHARMIGENE INC financial stats to get the full picture.
No, 7595 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMIGENE INC EBITDA is ‪−54.57 M‬ TWD, and current EBITDA margin is −27.75%. See more stats in PHARMIGENE INC financial statements.
Like other stocks, 7595 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMIGENE INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMIGENE INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMIGENE INC stock shows the strong sell signal. See more of PHARMIGENE INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.